Hormone Refractory Prostate Cancer Market Report 2026

Hormone Refractory Prostate Cancer Market Overview

• Hormone Refractory Prostate Cancer market size has reached to $8.12 billion in 2025 • Expected to grow to $13.09 billion in 2030 at a compound annual growth rate (CAGR) of 10% • Growth Driver: A Growing Investment In Cancer Research Worldwide Is Fueling The Growth Of The Market Due To Increasing Focus On Advanced Therapies And Precision Treatment Development • Market Trend: Advancement In Targeted Radioligand Therapy Gains Ground In Advancing Treatment For Resistant Prostate Cancer • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Hormone Refractory Prostate Cancer Market?

Hormone-refractory prostate cancer (HRPC), also known as castration-resistant prostate cancer (CRPC), is a form of prostate cancer that continues to progress despite achieving low testosterone levels through androgen deprivation therapy (ADT). This progression may be indicated by rising prostate-specific antigen (PSA) levels, radiographic evidence of new or growing tumors, or worsening clinical symptoms. Hormone-refractory prostate cancer (HRPC) represents a more advanced and treatment-resistant stage of prostate cancer, often requiring additional systemic therapies beyond standard hormone suppression. The main treatment types for hormone-refractory prostate cancer are chemotherapy, hormonal therapy, immunotherapy, radiation therapy, and surgery. Chemotherapy treats hormone-refractory prostate cancer by using powerful drugs to target cancer that no longer responds to hormone therapy and has spread. It is distributed through several distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and is used by various end users, including hospitals, ambulatory surgical centers, specialty clinics, and others.

What Is The Hormone Refractory Prostate Cancer Market Growth Forecast?

The hormone refractory prostate cancer market size is expected to see strong growth in the next few years. It will grow to $13.09 billion in 2030 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to increasing development of targeted therapies, rising clinical trial activity in castration-resistant prostate cancer, growing demand for personalized oncology care, expansion of immuno-oncology pipelines, increasing healthcare expenditure on cancer treatments. Major trends in the forecast period include increasing adoption of precision oncology therapies, rising use of combination drug regimens, growing integration of biomarker-based treatment selection, expansion of immunotherapy applications in advanced prostate cancer, enhanced focus on personalized treatment pathways.

What Is The Driver Of The Hormone Refractory Prostate Cancer Market?

A growing investment in cancer research is expected to propel the growth of the hormone-refractory prostate cancer market going forward. Cancer research investment involves funding and resource support to advance innovative cancer detection, treatment, and prevention approaches. The cancer research investment is rising due to the increasing global cancer burden, which demands more effective and targeted treatments. Investment in cancer research drives innovation in treating hormone-refractory prostate cancer by enabling advanced therapies such as radioligand treatments and hormone inhibitors. It also funds clinical trials and biomarker research to enhance treatment precision and outcomes. For instance, in August 2024, according to the Cancer Research Institute (CRI), a US-based nonprofit organization dedicated to advancing immunotherapy research, invested around $22.8 million in the 2023–2024 fiscal year, funding 64 new grants to researchers from 42 institutions across seven countries. Therefore, growing investment in cancer research is driving the growth of the hormone-refractory prostate cancer market.

Key Players In The Global Hormone Refractory Prostate Cancer Market

Major companies operating in the hormone refractory prostate cancer market are Pfizer Inc, Johnson And Johnson, F Hoffmann La Roche Ltd, Merck And Co Inc, AbbVie Inc, Bayer AG, Sanofi SA, Bristol Myers Squibb Company, Novartis AG, AstraZeneca Plc, Eli Lilly And Company, Amgen Inc, Astellas Pharma Inc, Ipsen Pharma, Exelixis Inc, Orion Corporation, Lantheus Holdings Inc, Clovis Oncology Inc, Telix Pharmaceuticals, Dendreon Pharmaceuticals LLC, Janssen Pharmaceuticals Inc, Bayer Healthcare Pharmaceuticals Inc

Global Hormone Refractory Prostate Cancer Market Trends and Insights

Major companies operating in the hormone-refractory prostate cancer market are focusing on developing advanced therapies, such as intravenous radioligand therapy, to improve survival rates in patients with resistant forms of the disease. Intravenous radioligand therapy is a targeted treatment that uses radioactive molecules attached to ligands to identify and bind to cancer-specific markers. It destroys cancer cells internally while sparing surrounding healthy tissue. For instance, in March 2025, Novartis AG, a Switzerland-based pharmaceutical corporation, launched Pluvicto (lutetium Lu 177 vipivotide tetraxetan), which received approval from the Food and Drug Administration (FDA). It is designed for earlier use in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with an androgen receptor pathway inhibitor (ARPI) and are appropriate to delay chemotherapy. The expanded indication, based on the Phase III PSMAfore trial, approximately triples the eligible patient population and showed that Pluvicto reduced the risk of radiographic progression or death by 59% and more than doubled median radiographic progression-free survival compared to a change in ARPI. Pluvicto is the first targeted radioligand therapy approved for use before chemotherapy in this setting, offering a new treatment option that delays disease progression with a favorable safety profile.

What Are Latest Mergers And Acquisitions In The Hormone Refractory Prostate Cancer Market?

In June 2024, AstraZeneca, a UK-based biopharmaceutical company, acquired Fusion Pharmaceuticals Inc. for $2.4 billion. This acquisition aims to enhance AstraZeneca’s oncology portfolio by adding next-generation radioconjugate therapies, including FPI-2265 for metastatic castration-resistant prostate cancer (mCRPC), and to strengthen its capabilities in radiopharmaceutical research and development, manufacturing, and supply. Fusion Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company that provides treatment for metastatic castration-resistant prostate cancer.

What Defines the Hormone Refractory Prostate Cancer Market?

The hormone-refractory prostate cancer (HRPC) market consists of revenues earned by entities by providing services such as oncology consultations, advanced imaging, molecular diagnostic testing, clinical trial participation, and palliative care. The market value includes the value of related goods sold by the service provider or included within the service offering. The hormone-refractory prostate cancer (HRPC) market also includes sales of next-generation androgen receptor inhibitors, radiopharmaceuticals, and bone health agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Hormone Refractory Prostate Cancer Market Report 2026?

The hormone refractory prostate cancer market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hormone refractory prostate cancer industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.